Are you Dr. Romaguera?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 113 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Summary
- Dr. Jorge Romaguera, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas and Puerto Rico. She is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1987 - 1988
University of Puerto RicoFellowship, Hematology and Medical Oncology, 1985 - 1987- University of Puerto RicoResidency, Internal Medicine, 1982 - 1985
- University of Puerto Rico School of MedicineClass of 1982
Certifications & Licensure
TX State Medical License 1988 - 2024
PR State Medical License 1986 - 2010- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2009-2013
Clinical Trials
- Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Start of enrollment: 1996 Aug 01
- Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Start of enrollment: 1998 May 20
- FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2006 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 19 citationsPre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphomaPaolo Strati, Mohamed Amin Ahmed, Nathan Fowler, Loretta J. Nastoupil, Felipe Samaniego, Luis Fayad, Fredrick B. Hagemeister, Jorge E. Romaguera, Alma Rodriguez, Micha...> ;Haematologica. 2020 Jul 1
- 50 citationsEfficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;American Journal of Hematology. 2020 Jun 1
- 39 citationsGenomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL., , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Blood Advances. 2020 Mar 24
- Join now to see all
Press Mentions
Non-Hodgkin’s Lymphoma Survivor Grateful for Fertility PreservationAugust 30th, 2018
Ibrutinib Has 'Unprecedented' Impact on Mantle Cell LymphomaDecember 14th, 2012- Intense Chemotherapy Wards off Recurrence in Half of Mantle Cell Lymphoma Patients After Seven YearsDecember 15th, 2008
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
